Residency · Residency · Obstetrics Gynecology

Osteoporosis Screening and Prevention in Women

Introduction

Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration leading to increased fracture risk. Postmenopausal women are disproportionately affected due to estrogen deficiency-mediated accelerated bone loss. Approximately 50% of women over age 50 will experience an osteoporotic fracture in their remaining lifetime. Prevention, early detection, and evidence-based management are critical responsibilities of the obstetrician-gynecologist.

Bone Biology and Pathophysiology

Normal Bone Remodeling

The bone remodeling cycle is a continuous process involving osteoclast-mediated resorption followed by osteoblast-mediated formation, with each complete cycle requiring 4-6 months. Peak bone mass is achieved by age 25-30 and is determined primarily by genetics (60-80%), with nutrition, physical activity, and hormonal status also contributing. The RANK/RANKL/OPG axis governs osteoclast differentiation: osteoblasts produce RANKL, which binds RANK on osteoclast precursors to promote their activation, while osteoprotegerin (OPG) acts as a decoy receptor that inhibits this pathway.

Estrogen Deficiency and Bone Loss

Estrogen suppresses osteoclast activity by promoting OPG production and suppressing RANKL expression, while also promoting osteoblast survival through anti-apoptotic effects. After menopause, an accelerated phase of bone loss occurs at 2-3% per year during the first 5-7 years, then slows to 0.5-1% per year. Trabecular bone (found in vertebral bodies, distal radius, and proximal femur) is lost preferentially due to its higher surface area and remodeling rate. Over a lifetime, women lose approximately 35-50% of trabecular and 25-30% of cortical bone.

Screening and Diagnosis

DXA Scanning

Dual-energy X-ray absorptiometry (DXA) is the gold standard for measuring bone mineral density (BMD). Measurements are taken at the lumbar spine (L1-L4), total hip, and femoral neck, with the lowest T-score used for diagnosis. The T-score represents the number of standard deviations from the mean BMD of a young adult reference population. Normal is defined as a T-score of -1.0 or greater, osteopenia as -1.0 to -2.5, osteoporosis as -2.5 or less, and severe osteoporosis as -2.5 or less with a fragility fracture.

Screening Recommendations

The USPSTF and ACOG recommend DXA screening for all women aged 65 and older. Younger postmenopausal women should be screened if their 10-year major osteoporotic fracture risk reaches 9.3% or greater by FRAX, which corresponds to the fracture risk of a 65-year-old white woman without additional risk factors. Risk factors that prompt earlier screening include prior fragility fracture, parental hip fracture, glucocorticoid use (5 mg or more prednisone equivalent for 3 months or longer), low BMI (less than 20), rheumatoid arthritis, smoking, and excessive alcohol intake. Screening is repeated every 2 years for women on treatment and every 2-5 years for untreated osteopenia depending on baseline T-score and risk profile.

<image>Illustration showing DXA scan positioning and output including a sample DXA report of the lumbar spine and proximal femur with T-scores, Z-scores, BMD values in g/cm2, and WHO classification thresholds for normal, osteopenia, and osteoporosis</image>

FRAX and Fracture Risk Assessment

The FRAX tool is a validated algorithm that estimates the 10-year probability of major osteoporotic fracture and hip fracture based on clinical risk factors, with or without BMD input. Treatment thresholds recommended by the NOF and AACE include a 10-year hip fracture probability of 3% or greater, a 10-year major osteoporotic fracture probability of 20% or greater, a T-score of -2.5 or less at any site, or a history of hip or vertebral fracture. The trabecular bone score (TBS) can be incorporated into FRAX as an adjustment for trabecular microarchitecture quality.

Secondary Causes of Osteoporosis

Secondary causes must be excluded before initiating treatment. Endocrine causes include hyperparathyroidism, hyperthyroidism, Cushing syndrome, hypogonadism, premature ovarian insufficiency, and type 1 diabetes. Medication-related causes include glucocorticoids (the most common drug-induced cause), aromatase inhibitors, GnRH agonists, anticonvulsants, proton pump inhibitors, heparin, and DMPA. Nutritional causes include vitamin D deficiency, calcium deficiency, celiac disease, eating disorders, and bariatric surgery. A basic laboratory workup includes CBC, comprehensive metabolic panel, 25-hydroxyvitamin D, TSH, and PTH, with celiac serologies, 24-hour urine calcium, and serum protein electrophoresis considered in selected patients.

Prevention Strategies

Nutrition

Calcium intake should be 1,000 mg/day for women 19-50 and 1,200 mg/day for women over 50, with dietary sources preferred and supplementation added if dietary intake is insufficient. Vitamin D requirements are 600-800 IU/day at minimum, though many experts recommend 1,000-2,000 IU/day with a target serum 25(OH)D of 30 ng/mL or greater. Adequate protein intake (1.0-1.2 g/kg/day) supports both bone and muscle health.

Exercise

Weight-bearing exercise such as walking, jogging, stair climbing, and dancing for 30 minutes most days stimulates osteoblast activity. Resistance training 2-3 sessions per week improves muscle strength and reduces fall risk. Balance training through tai chi or yoga reduces fall risk by 20-30% in older adults.

Fall Prevention

Home safety assessments should address tripping hazards, lighting, and grab bars. Medications that increase fall risk (sedatives, anticholinergics) should be minimized. Annual vision correction and, in high-risk institutional settings, hip protectors further reduce fracture occurrence.

Pharmacologic Treatment

Antiresorptive Agents

Bisphosphonates are first-line therapy for most patients. Options include oral alendronate (70 mg weekly), risedronate (35 mg weekly or 150 mg monthly), ibandronate (150 mg monthly oral or 3 mg IV quarterly), and zoledronic acid (5 mg IV annually). These agents reduce vertebral fracture risk by 40-70% and hip fracture by 40-50%. Drug holidays are considered after 5 years of oral therapy (or 3 years of IV therapy) in lower-risk patients, with reassessment guiding resumption.

Denosumab (Prolia) is a RANKL inhibitor administered as 60 mg subcutaneously every 6 months. It reduces vertebral, hip, and nonvertebral fractures. Critically, denosumab must never be discontinued abruptly because rebound bone loss and vertebral fractures can occur within months of stopping. Transition to a bisphosphonate must occur before or immediately after discontinuation.

Anabolic Agents

Teriparatide (Forteo) is recombinant PTH (1-34) given as 20 mcg subcutaneously daily for up to 2 years. It stimulates osteoblast activity and reduces vertebral fractures by 65%. Abaloparatide (Tymlos) is a PTHrP analogue (80 mcg subcutaneously daily for up to 2 years) that reduces both vertebral and nonvertebral fractures. Romosozumab (Evenity) is a sclerostin inhibitor (210 mg subcutaneously monthly for 12 months) with a dual mechanism that increases formation and decreases resorption, but carries an FDA black box warning for increased cardiovascular events and should be avoided in patients with recent MI or stroke. Anabolic agents should always be followed by antiresorptive therapy to maintain bone gains.

Hormone Therapy

Hormone therapy prevents postmenopausal bone loss and reduces fracture risk (the WHI showed a 34% reduction in hip fractures with CEE plus MPA). However, it is not recommended as first-line therapy for osteoporosis alone due to its risk profile. It is appropriate when prescribed for vasomotor symptoms in women who also have low bone mass. Discontinuation of HT leads to rapid bone loss similar to early menopause.

<image>Flowchart for osteoporosis management in postmenopausal women showing screening with DXA, risk stratification using T-scores and FRAX, and treatment algorithm with first-line bisphosphonates, second-line denosumab, and anabolic agents for severe osteoporosis, followed by monitoring with serial DXA</image>

Monitoring Treatment

DXA is repeated every 1-2 years during treatment. Stable or increasing BMD indicates response, while significant decline (greater than 3-5% at the spine or 4-5% at the hip) suggests nonadherence, a secondary cause, or treatment failure. Bone turnover markers (C-telopeptide for antiresorptive monitoring, P1NP for anabolic monitoring) can confirm medication adherence and therapeutic response within 3-6 months.

Clinical Pearls

All women aged 65 and older should be screened with DXA, and younger postmenopausal women should be screened when risk factors are present or FRAX-estimated fracture risk reaches 9.3%. Secondary causes of osteoporosis must be excluded before initiating treatment through a basic workup including 25(OH)D, calcium, TSH, and CBC. Bisphosphonate drug holidays are appropriate after 5 years of oral therapy in lower-risk patients, with reassessment by DXA and clinical risk factors guiding when to resume. Denosumab must never be abruptly discontinued because rebound vertebral fractures can occur within months; transition to a bisphosphonate is always required. Anabolic-first strategies (teriparatide or romosozumab followed by antiresorptive therapy) produce greater BMD gains than antiresorptive therapy alone and should be considered for severe osteoporosis.

References

1. ACOG Practice Bulletin No. 129 (Reaffirmed 2021). Osteoporosis. Obstet Gynecol. 2012;120(3):718-734.
2. US Preventive Services Task Force. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(24):2521-2531.
3. Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 2020;105(3):dgaa048.
4. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359-2381.

Read this lecture as Markdown